Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 1999, p. 510-513, Vol. 43, No. 3
Departamento de Patología Animal I,
Facultad de Veterinaria, Universidad Complutense, 28040 Madrid, Spain
Received 22 May 1998/Returned for modification 17 September
1998/Accepted 5 December 1998
The in vitro activities of several cephalosporins and quinolones
against 195 strains of Escherichia coli isolated from dairy calves affected by neonatal diarrhea were determined. One hundred thirty-seven of these strains produced one or more potential virulence factors (F5, F41, F17, cytotoxic necrotizing factor, verotoxin, and the
eae gene), but the remaining 58 strains did not produce any
of these factors. From 11 to 18% of the E. coli strains
were resistant to cephalothin, nalidixic acid, enoxacin, and
enrofloxacin. However, cefuroxime, cefotaxime, and cefquinome were
highly effective against the E. coli isolates tested. Some
significant differences (P < 0.05) in resistance to
quinolones between the strains producing potential virulence factors
and nonfimbriated, nontoxigenic, eae-negative strains were
found. Thus, eae-positive, necrotoxigenic, and
verotoxigenic (except for nalidixic acid) E. coli strains
were significantly more sensitive to nalidixic acid, enoxacin, and
enrofloxacin than nonfimbriated, nontoxigenic, eae-negative
strains. Moreover, eae-positive strains were significantly
more sensitive to enoxacin and enrofloxacin than F5-positive strains.
Thus, the results of this study suggest that the bovine E. coli strains that produce some potential virulence factors are
more sensitive to quinolones than those that do not express these factors.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro Activities of Cephalosporins and
Quinolones against Escherichia coli Strains Isolated from
Diarrheic Dairy Calves
*
Corresponding author. Mailing address: Departamento de
Patología Animal I, Facultad de Veterinaria, Universidad
Complutense, 28040 Madrid, Spain. Phone: 91-3943703. Fax: 91-3943908. E-mail: rifuente{at}eucmax.sim.ucm.es.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |